Covered recipient · General Payments record
PANKAJ KHETERPAL
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$5,043.45
- Reported across 140 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $729.27 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| DEXCOM, INC. | $448.33 | 6 |
| Acerta Pharma LLC | $105.60 | 1 |
| GlaxoSmithKline, LLC. | $45.22 | 2 |
| Abbott Laboratories | $36.24 | 2 |
| Exact Sciences Corporation | $22.00 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.43 | 1 |
| Lilly USA, LLC | $20.14 | 1 |
| Sumitomo Pharma America, Inc. | $16.18 | 1 |
| Novo Nordisk AS | $14.13 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.48 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125280498 | CMS |
| Abbott Laboratories | $13.76 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125280500 | CMS |
| AstraZeneca Pharmaceuticals LP | $105.60 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104781858 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.43 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118160882 | CMS |
| Dexcom, Inc. | $19.57 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153327153 | CMS |
| Dexcom, Inc. | $156.48 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153327155 | CMS |
| Dexcom, Inc. | $16.38 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153327157 | CMS |
| Dexcom, Inc. | $22.52 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153327159 | CMS |
| Dexcom, Inc. | $131.30 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153327161 | CMS |
| Dexcom, Inc. | $102.08 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153327163 | CMS |
| Exact Sciences Corporation | $22.00 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114733512 | CMS |
| GlaxoSmithKline, LLC. | $21.45 | 02/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116639670 | CMS |
| GlaxoSmithKline, LLC. | $23.77 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116174513 | CMS |
| Lilly USA, LLC | $20.14 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135270325 | CMS |
| Novo Nordisk Inc | $14.13 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096703776 | CMS |
| Sumitomo Pharma America, Inc. | $16.18 | 07/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148874045 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.